References
- Penglis P S, James M J, Cleland L G. Cyclooxygenase inhibitors: any reservations?. IMJ 2001; 31(1):37–41., [CSA]
- Fujita T, Yamashita N, Yamashita K. Effect of indomethacin on antihypertensive action of captopril in hypertensive patients.Clin Exp Hypertens 1981; 3:939–952., [PUBMED], [INFOTRIEVE], [CSA]
- Silverbauer K, Stanek B, Tempel H. Acute hypotensive effect of captopril modified by prostaglandin synthesis inhibition.Br J Clin Pharmacol 1982; 14:87S–93S., [CSA]
- FitzGerald G A, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system.Clin Exp Rheumatol 2001; 19(suppl 25):S31–S36., [PUBMED], [INFOTRIEVE], [CSA]
- Zhao S Z, Reynolds M W, Lejkowith J, Whelton A, Arellano F M. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre Safety database.Clin Ther 2001; 23(9):1478–1491., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cleland L G, James M J, Stamp L K, Penglis P S. COX-2 inhibition and thrombotic tendency: a need for surveillance.Med J Aust 2001; 175:214–217., [PUBMED], [INFOTRIEVE], [CSA]
- Dubey K, Balani D K, Pillai K K. Potential adverse interaction between aspirin and lisinopril in hypertensive rats.Human Exp Toxicol 2003; 22:143–147., [CSA], [CROSSREF]
- Nguyen K N, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality and morbidity after acute myocardial infarction: subgroup analysis of the Co-operative New Scandinavian Enalapril Survival Study II (CONSENSUS II).Am J Cardiol 1997; 79:115–119., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.Lancet 1993; 342:821–828., [CSA]
- Al-Khadra A S, Salem D N, Rand W M, Udelson J E, Smith J J, Konstam M A. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial.J Am Coll Cardiol 1998; 31:419–425., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, Behar S. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease.J Am Coll Cardiol 1999; 33:1920–1925., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Latini R, Tognoni G, Maggioni A P, Baigent C, Braunwald E, Chen Z, Collins R, Flather M, Franzosi M, Kjekshus J, Kober L, Liu L, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S, On Behalf of the Angiotensin-Converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Systematic overview of individual data from 96,712 randomized patients.J Am Coll Cardiol 2000; 35:1801–1807., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.Lancet 1995; 345:669–685., [CSA], [CROSSREF]
- Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats.Jpn Circ J 1963; 27:282–293., [PUBMED], [INFOTRIEVE], [CSA]
- Doggrell S A, Brown L. Rat models of hypertension, cardiac hypertrophy and failure.Cardiovasc Res 1998; 39:89–105., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rosskopf D, Düsing R, Siffert W. Membrane sodium-proton exchange and primary hypertension.Hypertension 1993; 21:607–617., [PUBMED], [INFOTRIEVE], [CSA]
- Feig P U, D'Occhio M A, Boylan J W. Lymphocyte membrane sodium-proton exchange in spontaneously hypertensive rats.Hypertension 1987; 9:282–288., [PUBMED], [INFOTRIEVE], [CSA]
- Berk B C, Vallega G, Muslin A J, Gordon H M, Canessa M, Alexander R W. Spontaneously hypertensive rat vascular smooth muscle cells in culture exhibit increased growth and Na+/H+ exchange.J Clin Invest 1989; 83:822–829., [PUBMED], [INFOTRIEVE], [CSA]
- Lucchesi P A, DeRoux N, Berk B C. Na+-H+ exchanger expression in vascular smooth muscle of spontaneously hypertensive and Wistar-Kyoto rats.Hypertension 1994; 24:734–738., [PUBMED], [INFOTRIEVE], [CSA]
- Orlov S N, Postnov I Y, Pokudin N I, Kukharenko V Y, Postnov Y V. Na+-H+ exchange and other ion-transport systems in erythrocytes of essential hypertensives and spontaneously hypertensive rats: a comparative analysis.J Hypertens 1989; 7:781–788., [PUBMED], [INFOTRIEVE], [CSA]
- Rosskopf D, Siffert G, Osswald U, Witte K, Düsing R, Akkerman J WN, Siffert W. Platelet Na+/H+ exchange activity in normotensive and hypertensive subjects: effect of enalapril therapy upon antiport activity.J Hypertens 1992; 10:839–847., [PUBMED], [INFOTRIEVE], [CSA]
- Fortuno A, Tisaire J, Lopez R, Bueno J, Diez J. Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension.Am J Hypertens 1997; 10:84–93., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Brilla C G, Janicki J S, Weber K T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy.Circulation 1991; 83(5):1771–1779., [PUBMED], [INFOTRIEVE], [CSA]
- Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar B M. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.Br J Pharmacol 2001; 132(7):1565–1573., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laudanno O M, Cesolari J A, Esnarriaga J, Rista L, Piombo G, Maglione C, Aramberry L, Sambrano J, Godoy A, Rocaspana A. Gastrointestinal damage induced by celecoxib and rofecoxib in rats.Dig Dis Sci 2001; 46(4):779–784., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- deBlois D, Tea B S, Dam T V, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats.Hypertension 1997; 29(2):340–349., [PUBMED], [INFOTRIEVE], [CSA]
- Black M J, Kanellakis P, Bobik A. Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats.J Hypertens 1997; 15:945–954., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Scholz W, Albus U, Linz W, Martorana P, Lang H J, Schölkens B A. Effects of Na+/H+ exchange inhibitors in cardiac ischemia.J Mol Cell Cardiol 1992; 24:731–740., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Scholz W, Albus U, Lang H J, Linz W, Martorana P A, Englert H C, Schölkens B A. Hoe 694, a new Na+/H+ exchange inhibitor and its effects in cardiac ischemia.Br J Pharmacol 1993; 109:562–568., [PUBMED], [INFOTRIEVE], [CSA]
- Jackson L M, Hawkey C J. COX-2 selective non steroidal anti-inflammatory drugs. Do they really offer any advantages?. Drugs 2000; 59(6):1207–1216., [PUBMED], [INFOTRIEVE], [CSA]
- Hochberg M C. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.Clin Exp Rheumatol 2001; 19(suppl 25):S15–S22., [PUBMED], [INFOTRIEVE], [CSA]
- Abramson S B, Furst D E, Hochberg M C, Patrono C. Controversies in COX-2 inhibitor therapy: closing remarks.Clin Exp Rheumatol 2001; 19(suppl 25):S77–S80., [PUBMED], [INFOTRIEVE], [CSA]
- Verma S, Szmitko P E. Coxibs and the endothelium.J Am Coll Cardiol 2003; 42(10):1754–1756., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cleland J GF. No reduction in cardiovascular risk with NSAIDs—including aspirin?. Lancet 2002; 359:92–93., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M B, Hawkey C J, Hochberg M C, Kvein T K, Schnitzer T J, The Vigor Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.N Engl J Med 2000; 343:1520–1528., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Silverstein F E, Faich G, Goldstein J L, Simon L S, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N M, Stenson W F, Burr A M, Zhao W W, Kent J D, Lefkowith J B, Verburg K M, Geis G S. Gastrointestinal toxicity with celecoxib vs. non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial.JAMA 2000; 284:1247–1255., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mukherjee D, Nissen S E, Topol E J. Risk of cardiovascular events associated with selective COX-2 inhibitors.JAMA 2001; 286(8):954–959., [PUBMED], [CSA], [CROSSREF]
- Wallace J L, Bak A, Mcknight W, Asfaha S, Sharkey K A, MacNaughton W K. Cyclooxygenase-1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.Gastroenterology 1998; 115:101–109., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Catella-Lawson F, McAdam B, Morrison B W, Kapoor S, Kujubu D, Antes L, Lasseter K C, Quan H, Gertz B J, FitzGerald G A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.J Pharmacol Exp Ther 1999; 289(2):735–741., [PUBMED], [INFOTRIEVE], [CSA]
- Whelton A, Brater D C, Sica D A. Effects of celecoxib and naproxen on renal function in the elderly.J Am Soc Nephrol 1999; 10:92A., [CSA]
- Höcherl K, Endemann D, Kammerl M C, Grobecker H F, Kurtz A. Cyclooxygenase-2 inhibition increases blood pressure in rats.Br J Pharmacol 2002; 136:1117–1126., [CSA], [CROSSREF]
- Whelton A, White W B, Bello A E, Puma J A, Fort J G, SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis.Am J Cardiol 2002; 90(9):959–963., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Whelton A, Fort J G, Puma J A, Normandin D, Bello A E, Verburg K M, SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardio renal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.Am J Ther 2001; 8(2):85–95., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sandler D P, Burr R, Weinberg C R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease.Ann Intern Med 1991; 115(3):165–172., [PUBMED], [INFOTRIEVE], [CSA]
- Whelton A, Hamilton C W. Nonsteroidal anti-inflammatory drugs: effects on kidney function.J Clin Pharmacol 1991; 31:588–598., [PUBMED], [INFOTRIEVE], [CSA]
- Kendell M J, Horton R C. Clinical pharmacology and therapeutics.Postgrad Med J 1990; 66:166–185., [CSA]
- Harris R C, McKanna J A, Akai Y, Jacobson H R, Dubois R N, Breyer M D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.J Clin Invest 1994; 94:2504–2510., [PUBMED], [INFOTRIEVE], [CSA]
- Harris R C, Breyer M D. Physiological regulation of cyclooxygenase-2 in the kidney.Am J Physiol, Renal 2001; 281:F1–F11., [CSA]
- Lorenz J N, Greenberg S G, Briggs J P. The macula densa mechanism for control of renin secretion.Semin Nephrol 1993; 13(6):531–542., [PUBMED], [INFOTRIEVE], [CSA]
- Fitzgerald D J, Roy L, Catella F, FitzGerald G A. Platelet activation in unstable coronary disease.N Engl J Med 1986; 315:983–989., [PUBMED], [INFOTRIEVE], [CSA]
- Shinmura K, Tang X L, Wang Y, Xuan Y T, Liu S Q, Takano H, Bhatnagar A. Cyclooxygenase-2 mediates the cardioprotective effects of ischemic preconditioning in conscious rabbits.Proc Natl Acad Sci U S A 2000; 97:10197–10202., [PUBMED], [INFOTRIEVE], [CSA]
- Naproxen: Long term study indicates cardiovascular risk. WHO Pharmaceuticals Newsletter, prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 2005; 1:4., [CSA]
- FDA Alert for Practitioners (Celecoxib), 17 December 2004, , Available at http://www.fda.gov.
- Hall D. The aspirin-angiotensin converting enzyme inhibitor trade off: to halve and halve not.J Am Coll Cardiol 2000; 35:1808–1812., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Adams M A, Bobik A, Komer P I. Differential development of vascular and cardiac hypertrophy in genetic hypertension.Hypertension 1989; 14:191–201., [PUBMED], [INFOTRIEVE], [CSA]
- McGuire P G, Tweitmeyer T A. Aortic endothelial functions in developing hypertension.Hypertension 1985; 7:483–490., [PUBMED], [INFOTRIEVE], [CSA]
- Ambrosioni E, Costa F V, Montebrignoli L, Tartagni F, Magnani B. Increased intralymphocytic sodium content in essential hypertension: an index of impaired Na+ cellular metabolism.Clin Sci 1981; 61:181–186., [PUBMED], [INFOTRIEVE], [CSA]
- Hilton P. Cellular sodium transport in essential hypertension.N Engl J Med 1986; 314:222–229., [PUBMED], [INFOTRIEVE], [CSA]
- Parker J C, Berkowitz L R. Physiologically instructive genetic variants involving in human red cell.Physiol Rev 1983; 63:261–313., [PUBMED], [INFOTRIEVE], [CSA]
- Simon G. Is intracellular sodium increased in hypertension?. Clin Sci 1989; 76:455–461., [PUBMED], [INFOTRIEVE], [CSA]
- Siffert W, Düsing R. Sodium-proton exchange and primary hypertension. An update.Hypertension 1995; 26:649–655., [PUBMED], [INFOTRIEVE], [CSA]
- Canessa M, Morgan K, Goldszer R, Moore T J, Spalvins A. Kinetic abnormalities of the red blood cell sodium-proton exchange in hypertensive patients.Hypertension 1991; 17:340–348., [PUBMED], [INFOTRIEVE], [CSA]
- Karmazyn M, Sostaric J V, Gan X T. The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure.Drugs 2001; 61(3):375–389., [PUBMED], [INFOTRIEVE], [CSA]